Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 13/20 | 0.74 |
| ▸ | PIK3R1 | P27986 | 11/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | STK4 | Q13043 | 1/20 | 0.50 |
| ▸ | STK3 | Q13188 | 1/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.50 |
| ▸ | GAK | O14976 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL632723 | 0.85 | PIK3CA (0.64) | PIK3CAPIK3R1 | |
| SCHEMBL893488 | 0.85 | PIK3CA (1.00) | PIK3CAPIK3R1 | |
| SCHEMBL16881785 | 0.84 | CYP1A2 (0.53) | PIK3CAPIK3R1CYP1A2CYP3A4TSHR | |
| SCHEMBL14725956 | 0.82 | PIK3CA (0.50) | PIK3CAPIK3R1CYP1A2CYP3A4TSHR | |
| SCHEMBL20458862 | 0.82 | CYP1A2 (0.51) | PIK3CAPIK3R1CYP1A2CYP3A4TSHR | |
| SCHEMBL16881772 | 0.81 | PIK3CA (0.55) | PIK3CAPIK3R1CYP1A2CYP3A4TSHR | |
| SCHEMBL5561579 | 0.81 | CYP1A2 (0.49) | PIK3CAPIK3R1CYP1A2CYP3A4TSHR | |
| SCHEMBL14716698 | 0.80 | CYP1A2 (0.50) | PIK3CAPIK3R1CYP1A2CYP3A4TSHR | |
| SCHEMBL632859 | 0.79 | PIK3CA (0.68) | PIK3CAPIK3R1ALDH1A1 | |
| SCHEMBL633371 | 0.79 | CYP1A2 (0.48) | PIK3CAPIK3R1CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2419429-B1 | IMIDAZOPYRAZINES AS INHIBITORS OF PROTEIN KINASES | CT NAC INVESTIGACIONES ONCOLOGICAS CNIO (ES) | 2014-03-26 | — | — | EP | claimed |
| US-8778935-B2 | Imidazopyrazines for use as kinase inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-07-15 | — | — | US | disclosed |
| WO-2012052745-A1 | COMBINATIONS OF PI3K INHIBITORS WITH A SECOND ANTI -TUMOR AGENT | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-04-26 | — | — | WO | disclosed |
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2012-04-05 | — | — | US | disclosed |
| EP-2419429-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010119264-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCÓLOGICAS (CNIO) (ES) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | MTOR, PIK3CA, PI4KA | PIK3CA 2/4885PIK3R1 6/4885CYP1A2 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.